Global pharmaceutical company Lupin Limited (Lupin) has received approval from the United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Applications (ANDAs) for Amifampridine Tablets, 10 mg. As one of the first ANDA applicants, Lupin is eligible for 180 days of shared generic exclusivity.
Lupin’s Amifampridine Tablets, 10 mg, have been determined to be bioequivalent to the reference listed drug (RLD), Firdapse® Tablets, 10 mg, marketed by Catalyst Pharmaceuticals, Inc. The product is approved for the indication specified in the approved labelling.
The FDA approval marks an addition to Lupin’s U.S. pharmaceutical portfolio and strengthens its presence in the generics market. The shared generic exclusivity eligibility provides the company with an opportunity to participate in the initial period of generic market entry for the product.
Lupin has an established presence in the United States, supported by a diversified portfolio that includes generics, complex generics, specialty medicines and biosimilars. The company continues to focus on expanding its product offerings and strengthening its position across key therapeutic categories.
Headquartered in Mumbai, India, Lupin operates across India, the U.S., other developed markets and emerging markets, with its products distributed in more than 100 markets. The company has a strong presence in cardiovascular, respiratory, diabetes, gastrointestinal and women’s health, with leadership positions in the U.S. and Indian markets across these therapeutic areas.
Its manufacturing and research infrastructure includes 15 state-of-the-art manufacturing facilities and six research centres, supported by a workforce of more than 26,000 professionals. These capabilities underpin the company’s development, manufacturing and supply of pharmaceutical products for markets around the world.
Beyond medicines, Lupin is expanding its healthcare ecosystem through diagnostics, digital health, patient-support programmes and disease-management initiatives. Sustainability also remains a core pillar of its business strategy. The approval of Amifampridine Tablets, 10 mg, adds to Lupin’s portfolio of products in the US market and reflects its continued focus on developing and commercialising pharmaceutical products across its key markets.
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with a presence across India, the US other developed markets and emerging markets. Its products are distributed in more than 100 markets. The company’s portfolio spans generics, complex generics, specialty medicines and biosimilars.
Lupin has established positions in cardiovascular, respiratory, diabetes, gastrointestinal and women’s health. Its operations are supported by 15 manufacturing facilities, six research centres and more than 26,000 professionals. The company is also developing its healthcare ecosystem through diagnostics, digital health, patient-support programmes and disease-management initiatives, with sustainability integrated into its business strategy.